Nuance Acquires Sino Health in a Deal Worth at Least $32 Million

Shanghai Nuance Pharma acquired Sino Health Pharmaceutical together with two of its subsidiaries in a deal worth "multi hundred million RMB" -- at least $32 million. Sino Health has three commercial stage products and a candidate under NDA review in China , plus a sales force of over 100 people. Nuance expects the acquisition to increase its presence in emergency care and retail sales, while also adding to its sales and distribution network. Nuance offers high-quality products and services that address unmet China medical needs. More details.... Share this with colleagues: // //